Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07110246 · ClinicalTrials.gov registry record · Phase 2
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
A Phase 2 study of Low Grade Glioma and Low Grade Glioma of Brain, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 4
- Study locations
NCT07110246: Recruiting Phase 2 study of Low Grade Glioma and Low Grade Glioma of Brain, sponsored by University of California, San Francisco.
NCT07110246 is a Phase 2 study of Low Grade Glioma and Low Grade Glioma of Brain that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 96 participants, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (13% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07110246, a Phase 2 study of Low Grade Glioma and Low Grade Glioma of Brain, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.
Primary Outcome
The Rebound rate is defined as increase in tumor size by 25% or more by Response Assessment in Pediatric Neuro-Oncology-Low Grade Glioma (RAPNO-LGG) criteria and/or clinical progression necessitating the re-institution of therapy occurring within 4 months off therapy for participants with BRAF V600 mutant LGG after abruptly stopping or weaning off dabrafenib and trametinib. RR will be reported by cohort and arm.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG Trametinib
- PROCEDURE Specimen Collection
- DRUG Dabrafenib
- PROCEDURE Optional Lumbar puncture
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Francisco - San Francisco
Maryland
- John Hopkins Medical Center - Baltimore
Missouri
- St. Louis Children's Hospital Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2032-03-31 |
| Phase | Phase 2 |
What NCT07110246 shows while recruiting
NCT07110246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (13% lower).
The record links to 4 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT07110246 reports a single indexed study location in Alabama, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07110246 about?
NCT07110246 is a clinical study titled "Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas". This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal...
What is the current status of trial NCT07110246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-11-07. Estimated completion is 2032-03-31.
What conditions does trial NCT07110246 study?
This clinical trial studies the following conditions: Low Grade Glioma, Low Grade Glioma of Brain, BRAF V600 Mutation, Recurrent Low Grade Glioma.
What interventions are being tested in trial NCT07110246?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Trametinib (DRUG), Specimen Collection (PROCEDURE), Dabrafenib (DRUG), Optional Lumbar puncture (PROCEDURE).
Who is sponsoring clinical trial NCT07110246?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07110246 being conducted?
This trial has 4 study locations across Alabama, California, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07110246's enrollment target sits among peer trials
96 13th of 23 higher than 11 of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI